Retail Investors Buy the Dip in Novo After Disappointing Weight-Loss Drug Data
U.S. retail investor fund flows into Novo Nordisk (NYSE: NVO) surged 32-fold on Friday, as the Danish drugmaker’s weaker-than-expected obesity […]
Retail Investors Buy the Dip in Novo After Disappointing Weight-Loss Drug Data Read More »